
Elke Jäger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5618811/publications.pdf Version: 2024-02-01



<u>Εικε Ι</u>Δάσερ

#	Article	lF	CITATIONS
1	Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. Journal of Experimental Medicine, 2020, 217, .	4.2	58
2	Clinically Relevant Immune Responses against Cytomegalovirus: Implications for Precision Medicine. International Journal of Molecular Sciences, 2019, 20, 1986.	1.8	6
3	NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma. Cancer Immunology, Immunotherapy, 2018, 67, 237-246.	2.0	12
4	Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17945-17950.	3.3	556
5	The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer. International Journal of Cancer, 2007, 120, 2635-2642.	2.3	31
6	NYâ€ESOâ€1: Review of an Immunogenic Tumor Antigen. Advances in Cancer Research, 2006, 95, 1-30.	1.9	311
7	In vivo antigen delivery by aSalmonella typhimurium type III secretion system for therapeutic cancer vaccines. Journal of Clinical Investigation, 2006, 116, 1946-1954.	3.9	164
8	Antigen-specific immunotherapy and cancer vaccines. International Journal of Cancer, 2003, 106, 817-820.	2.3	83
9	CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11813-11818.	3.3	83
10	Clinical cancer vaccine trials. Current Opinion in Immunology, 2002, 14, 178-182.	2.4	115
11	Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL. Journal of Immunology, 2000, 165, 948-955.	0.4	161
12	ldentification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma. Journal of Experimental Medicine, 2000, 191, 625-630.	4.2	196
13	Clonal expansion of melan a-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. International Journal of Cancer, 2000, 86, 538-547.	2.3	105
14	Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1. International Journal of Cancer, 1999, 80, 219-230.	2.3	667
15	Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. International Journal of Cancer, 1997, 71, 142-147.	2.3	287
16	Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptidesin vivo. , 1996, 67, 54-62.		261